Keros Therapeutics, Inc. — Form 8-K Summary
Report date: September 29, 2026. This is an event report, not a periodic financial report; it does not provide a financial reporting period.
Business context and event
Keros announced that it will receive a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under the elritercept license agreement. The milestone was triggered by dosing the first patient in ELRiSE MF, a Phase 3 trial testing elritercept against placebo in patients with myelofibrosis and anemia receiving concurrent ruxolitinib therapy.
Financial information
The filing reports the $20 million milestone payment but gives no clear payment date or information on its recognition in revenue, cash flow, or financial statements. It provides no revenue, profit, margin, cash, debt, or liquidity metrics.
Outlook, risks, and contingencies
No financial guidance or broader outlook is provided. The milestone is associated with clinical-trial progress; the filing does not describe other payment terms, future milestones, or trial outcomes. ELRiSE MF remains a clinical study, and the filing provides no efficacy or safety results.
Investor facts to verify
- When the $20 million payment is expected to be received and how Keros will account for it.
- The full license-agreement terms, including any remaining development or commercial milestones and royalties.
- ELRiSE MF enrollment, timing, and subsequent clinical updates.